Treatment and outcome

The patient was started on hydroxyurea, allopurinol, and hydration. Imatinib 400mg p.o/day was begun after cytoreduction.
She received conservative care for the hematoma accumulation and was discharged with appointments to the surgery and hematology clinics. In two weeks, she has significantly improved.

Conclusion

It is important to keep in mind that unexplained soft tissue hematoma can be an initial manifestation of chronic myelogenous leukemia. However, the exact cause of the Morel Lavallee lesion is not yet known, platelet dysfunction, acquired Von Willebrand disease, and acquired Glanzmann’s thrombasthenia are the most likely causes. supportive care and tyrosine kinase inhibitors are the main mode of management. Surgical interventions can be considered based on indications.